Evidence map›Paper›PMID 40986223›Full record

Observational studySleep & breathing = Schlaf & Atmung2025

Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.

Sarah Dietz-Terjung, Svenja Straßburg, Christoph Schöbel, Tim Schulte, Paul Dietz, Fatma Ezzahra Gahbiche, Jose Ortiz, Christian Taube, Gerhard Weinreich, Sivagurunathan Sutharsan and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah Dietz-TerjungDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany. sarah.terjung@uk-essen.de.ORCID 0000-0001-7907-6670
Svenja StraßburgDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Christoph SchöbelDepartment of Sleep and Telemedicine, University Hospital Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Tim SchulteDepartment of Sleep and Telemedicine, University Hospital Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Paul DietzDepartment of Sleep and Telemedicine, University Hospital Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Fatma Ezzahra GahbicheDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Jose OrtizDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Christian TaubeDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Gerhard WeinreichDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Sivagurunathan SutharsanDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Matthias WelsnerDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor/tezacaftor/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with ≥ 1 F508del allele during ETI therapy. The device's suitability for home monitoring of therapy success was also assessed.

methodsIn a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One + at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.

resultsSignificant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1-5 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.

conclusionSleepiz One + reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.

Indexed as

AminophenolsBenzodioxolesCystic FibrosisIndolesMonitoring, AmbulatoryPolysomnographyPyrazolesPyridinesPyrrolidinesQuinolonesAdolescentAdultDrug CombinationsFemaleHeart RateHumansAminophenolsBenzodioxolesDrug CombinationselexacaftorIndolesPyrazolesPyridinesPyrrolidinesQuinolonestezacaftor, ivacaftor drug combinationCystic fibrosisETI therapyInfection detectionRespiratory rateSleepiz one++Sleep monitoring

Identifiers

PMID40986223
PMCPMC12457222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.